This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites. The plasma cell dyscrasias investigated include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, plasmacytoma, immunoglobulin deposition diseases (primary amyloidosis and systemic light and heavy chain deposition diseases), and Waldenstroem's macroglobulinemia. In the case of multiple myeloma, the coverage ranges from genomic aberrations and microRNAs to treatment for different patient groups, upcoming novel therapies, immunotherapy, and transplantation. The book reflects the significant research advances achieved in this field during the past few years, which have enhanced our understanding of the molecular mechanisms responsible for the pathogenesis of plasma cell dyscrasias.

The fight against breast cancer is expected to be effectively stimulated by interdisciplinary approaches and cross-fertilization between laboratory and clinical research findings. Of major importance are therefore meetings promoting fast transfer to clinical applications of findings by basic scientists. The present volume, reporting the proceedings of the 1991 Biennial Conference of the International Association for Breast Cancer Research, hopes to achieve this goal by presenting the most recent observations in the laboratory and their possible applications for diagnostic evaluations and clinical treatments. The sections of the book focus first on the oncogenes more likely involved in mammary tumorigenesis and on the polypeptide factors and steroid hormones affecting proliferation and possibly inducing carcinogenesis in breast epithelium. A section is devoted to the epidemiological studies and to the identification of risk factors, a way to select populations at higher risk and, possibly, to help in preventing the disease. Special emphasis is given to the establishment of diagnostic criteria and to the selection of prognostic factors, which must support an effective therapeutic planning. It is our hope that this volume, a timely update of the most recent advances in specific fields presented by basic scientists, pathologists and clinicians will stimulate new insights and progresses leading ultimately to the control of breast cancer.

Cell based impedance sensing is becoming a new biophysical and cellular technology in cell based analyses. The technology has been used in investigation of cellular growth and death, cell adhesion and migration, cell invasion and cell-cell interactions, cell toxicity, angiogenesis, cell permeability, signal transduction and cellular behaviour under flow conditions. It is a probe free, highly sensitive, and versatile technology platform. Recent development in the technology has also allowed high throughput, automated analyses. It has been widely explored in chemistry, toxicity, cell biology, cancer biology, and other areas of chemistry, medicinal chemistry, life and medical science. Written by experts in the area of cell impedance sensing, including the Nobel Laureate Dr Ivar Giaever, this books covers the background of electric cell-substrate impedance sensing, their applications in cell based investigations, particularly in the area of cancer biology. This book is the first on this technology platform and will be a highly useful reference for molecular and cell biologists, cancer biologists, chemists and biochemists, clinical researchers who work in the areas of cell biology, molecular biology, toxicology, pharmaceutical industry, life science and medical research.

The study of immunology encompasses a vast and ever-growing body of information that in some way or other incorporates most areas of medical biological research. As the body of information in the medical sciences continues to increase its rate of expansion, one of the greatest challenges to investigators will be to integrate this information in a manner that is intellectually fruitful and productive. Considering the intended scope of this text, we could not pretend to have gone too far toward achieving such an integration--and considering the pace of change, in its very best form a measured approximation of such lofty goals might be the most we could hope for. Nevertheless, in these pages we have sought to produce a collection of information that is at once concise and up-to-date regarding areas where important developments are impacting on the way we understand the vertebrate immune system. In addition, although the information is geared toward advanced study, we have discussed some basic elements and concepts that we hope make the text a useful resource for both the immunologist and the nonspecialist. The intention is to provide the researcher, clinician, or advanced undergraduate student with a brief ov- view of specific components of the immune system, and to provide a place from which to begin further detailed study if necessary. To this end, we made every effort to supply extensive referencing--although limitations in space prevented exhaustive or complete referencing in some cases.

Pituitary adenomas account for 10-15% of all intracranial tumors and they frequently impair fertility. The development of medical and surgical therapy for such tumors has turned pregnancy into a reality for women harboring pituitary adenomas. However, gestation risks for both mother and fetus are still of concern for endocrinologists, gynecologists and pediatricians. This book intends to update knowledge on this topic, mainly regarding fertility restoration as well as gestational and post gestational management of patients with pituitary tumors.

Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II, and III clinical trials. With this in mind, the editors of Intraperitoneal Chemotherapy have assembled a team of highly experienced clinicians and researchers to cover every aspect of the subject. The topics addressed include treatment principles, patient, drug, and catheter selection, administration guidelines, the role of hyperthermia, supportive care requirements, novel drugs, and the most recent results of clinical trials. This book will be an invaluable source of information for both practicing clinical oncologists and oncologists in training.

With increasing numbers of reports on surgical and nonsurgical treatment of acoustic neuroma, standardization of reporting systems has become more and more important. For that purpose, the 11th Keio International Symposium for Life Sciences and Medicine, the Consensus Meeting on Systems for Reporting Results in Acoustic Neuroma, brought together researchers from Japan and other parts of the world. This volume is a compilation of papers from the symposium on standardization of evaluation and reporting systems for acoustic neuroma from such aspects as tumor size, facial nerve function, pre- and postoperative hearing, the effect of radiotherapy, and neurological symptoms. This unique book is a valuable reference for clinicians, researchers, and other professionals working in neurootology, neurosurgery, otolaryngology, audiology, and related fields.

In our environmentally conscious society, reports of an increase in the risk of developing several cancers - including melanoma, lymphoma and lung cancer - have excited great controversy. Of these tumors, melanoma has demonstrated the most spectacular increase, generating a considerable body of research. The justification for this volume is found in the need for an up-to-date review of this research. The book represents a comprehensive review of both current research and clinical management of melanoma, arranged in such a way as to be maximally user-friendly to both the basic scientst and the clinician interested in this fascinating disease.

This text provides a comprehensive overview of orthopaedic oncology - the field of orthopaedic surgery that specializes in the evaluation and treatment of bone and soft tissue tumors of the musculoskeletal system. The opening chapters cover musculoskeletal imaging interpretation and the principles of musculoskeletal biopsy. Assessment and treatment of the full range of tumors are then described in a series of well-illustrated chapters. Detailed consideration is given to benign tumors, osteosarcomas, Ewing sarcomas, chondrosarcomas, metastatic bone disease of the axial and appendicular skeleton, and soft tissue sarcomas. This book will be invaluable for both orthopaedic surgeons and medical oncologists, providing a framework for understanding the fundamentals of these tumors and a sound basis for their treatment.

In this issue of Hematology/Oncology Clinics, guest editor Dr. Harold J. Burstein brings his considerable expertise to Breast Cancer. Top experts provide a comprehensive update on multidisciplinary management of early- and late-stage breast cancer, including key topics such as global perspectives on the epidemiology and treatment of breast cancer; breast cancer pathology in the era of genomics; optimizing radiation therapy after breast conserving surgery; and more. Contains 16 relevant, practice-oriented topics including disparities in breast cancer outcomes and how to resolve them; genetic testing in breast cancer; the role of ovarian suppression in early stage premenopausal breast cancer; multidisciplinary management of brain metastases from breast cancer; evidence-based guidance for breast cancer survivorship; and more. Provides in-depth clinical reviews on breast cancer, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Proceedings of the Fifth International Symposium, held in Abano Terme (Padova), italy, June 29-July 2, 1987

One of the most exciting areas of cancer research now is the development of agents which can target signal transduction pathways that are activated inappropriately in malignant cells. The understanding of the molecular abnormalities which distinguish malignant cells from their normal counterparts has grown tremendously.
This volume summarizes the current research on the role that signal transduction pathways play in the pathogenesis of cancer and how this knowledge may be used to develop the next generation of more effective and less toxic anticancer agents.
Series Editor comments:
"The biologic behavior of both normal and cancer cells is determined by critical signal transduction pathways. This text provides a comprehensive review of the field. Leading investigators discuss key molecules that may prove to be important diagnostic and/or therapeutic targets."

The decade of the 1990s will see an increasing emphasis on the modulation of chemotherapeutic drug selectivity and in the 'lock and key' approach to new targets to control malignant proliferation. The contents of this volume appropriately reflect these scientific undercurrents. An emerging powerful tool of molecular pharmacology is described by Holcenberg and Wu. Manipulation of genetic expression by modification of messenger RNA is now within our reach, and the basic concepts are suc- cinctly reviewed as a primer on future biochemical engineering of new anti- cancer molecules. Another concept that appears to be worthy of further study in both experimental and clinical chemotherapy concerns obs'ervations on the modulation of activity by the nucleoside transport inhibitor, dipyri- damole. How potentiation of several anticancer drugs occurs has practical, as well as theoretical, ramifications, discussed by Goel and HowelL Finally, O'Dwyer and La Creta present a fresh look at sensitization of chemotherapy by the hypoxic radiosensitizer, SR-2731.

Brain Neurosecretory Cytokines: Immune Response and Neuronal Survival summarizes the biological and chemical data of signal molecules of the brain neuroendocrine immune system, mainly proline-rich peptides, which play an important role in the regulation of immune response, neuronal survival, hematopoiesis, and adaptation. The author also describes the role of PRPs for the protection of neurons against neurodegenerative disturbances and diseases.
Brain Neurosecretory Cytokines: Immune Response and Neuronal Survival will be of great aid to the researchers and students in various areas of neurobiological profile (neurochemistry, neuroendocrinology, neurophysiology, and endocrinology).

about the involvement of signaling Transforming growth factor in tumor development and metastasis. plays a central role in the signaling network that controls morphogenesis, 2. THE BASICS OF growth and cell differentiation in SIGNALING multicellular organisms. The different members of this pleiotropic family of 2. 1. receptor signaling growth and differentiation factors seem to The family of growth factors regulate many processes in human disease consists of more than thirty members in and, in particular, tumor development. humans alone (15, 16). They cluster in Our understanding of how two major groups, the group composed of initiated signals are mediated has both the bone morphogenetic proteins increased dramatically in the last fifteen (BMP) and growth and differentiation years. Firstly, the prototype of factors (GDFs), and the group formed by this still constantly growing family, was the Activins, and Nodals. The two identified and cloned (1). Secondly, the groups differ in their use of receptors for family receptors were transmembrane receptors and the identified by expression cloning from subsequent activation of the mammalian tissue culture (2-7). Thirdly, transcriptional mediators (for recent genetic screens in Drosophila reviews see (13, 14, 17)).

This work describes the importance of tumor microenvironment in favouring tumor progression and angiogenesis. Under physiological conditions, angiogenesis is dependent on the balance of positive and negative angiogenic modulators within the vascular microenvironment and requires the functional activities of a number of molecules, including angiogenic factors, extracellular matrix proteins, adhesion molecules and proteolytic enzymes. In normal tissues, vascular quiescence is maintained by the dominant influence of endogenous angiogenesis inhibitors over angiogenic stimuli. Tumor angiogenesis is linked to a switch in the balance between positive and negative regulators, and mainly depends on the release by inflammatory or neoplastic cells of specific growth factors for endothelial cells, that stimulate the growth of the blood vessels of the host or the down-regulation of natural angiogenesis inhibitors. In particular, the inflammatory infiltrate may contribute to tumor angiogenesis, and there are many reports of associations between tumor inflammatory infiltrate, vascularity and prognosis. New therapeutic approaches have been developed with the aim to control tumor angiogenesis through targeting of different components of tumor microenvironment.

In this issue of Hematology/Oncology Clinics, guest editors Drs. Matthew B. Yurgelun and Douglas A. Rubinson bring their considerable expertise to the topic of Pancreatic Cancer. Top experts in the field cover key topics such as pancreatic adenocarcinoma: trends in epidemiology, risk factors, and outcomes; decision making regarding perioperative therapy in individuals with localized pancreatic adenocarcinoma; the evolving role of radiotherapy in the management of individuals with pancreatic adenocarcinoma; and more. Contains 14 relevant, practice-oriented topics including diabetes, cachexia, sarcopenia, and metabolic factors in individuals with pancreatic adenocarcinoma; PARP inhibitors and other novel therapeutics in pancreatic adenocarcinoma; screening and surveillance for pancreatic adenocarcinoma in high-risk individuals; germline testing for individuals with pancreatic adenocarcinoma and novel genetic risk factors; and more. Provides in-depth clinical reviews on pancreatic cancer, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Thoracic Surgery Clinics, guest editors Drs. Jonathan Yeung and Elena Elimova bring their considerable expertise to the topic of Esophageal Cancer. Nearly 20,000 new cases of esophageal cancer are diagnosed each year in the U.S. alone. In this issue, top experts provide a timely update of this perennially important topic with coverage of pathology, genetics, staging, adjuvant therapies, and surgical management, as well as two special articles on controversies in esophageal cancer. Contains 12 practice-oriented topics, including staging of esophageal cancer; endoscopic treatment of esophageal cancer; immunotherapy and targeted therapy for esophageal cancer; Ongoing Controversies in Esophageal Cancer I: feeding tubes, pyloroplasty, thoracic duct clipping; Ongoing Controversies in Esophageal Cancer II: gastrectomy vs esophagectomy for Siewert 2 esophageal cancer; and more. Provides in-depth clinical reviews on esophageal cancer, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Basophils and mast cells are similar but unique secretory cells with a well-documented role in immediate-hypersensitivity reactions. The presence of these cells in various cell mediated hypersensitivity reactions, in tissues of multiple diseases, and as a component of the host reaction to injury and repair in numerous circumstances is well known. Release of stored and newly generated mediators of inflammation from basophils and mast cells contributes to the cascade of pathogenetic events in circumstances under which these release reactions occur. Despite insights acquired through studies of these pathologic events, the role of basophils and mast cells and their secretory products in health is not known. In this book, I review much of the structural information regarding basophils and mast cells of multiple species. Ultrastructural studies of rat mast cells historically precede and quantitatively exceed similar studies of basophils and mast cells of other species. Therefore, I first review these background studies as an entity. Then I discuss the contents of two prominent organelles-granules and lipid bodies-in basophils and mast cells of several species. The ultrastructural morphology of basophils and mast cells in three species is presented in detail to establish appropriate guidelines for their recognition and to provide general rules for analysis which are appropriate for the identification of these cells in other species as well."

The addition of chemotherapy as an effective means to treat cancer has had a major impact on selected human malignancies. Due to a general inability to dif ferentiate between normal and neoplastic cells, little selectivity exists in currently used oncolytic drugs. Consequently, significant toxicity to the patient is expected when systemic cancer chemotherapy is chosen as an appropriate therapeutic in tervention. Much of this toxicity, such as damage to the bone marrow, gastroin testinal tract, or hair follicles, is predictable based upon the fact that anticancer drugs kill actively dividing cells. These types of toxicities, while serious, are usually manageable and reversible and are, therefore, not often considered to be dose limiting. Unfortunately, several of the most important anticancer drugs also damage tissues in which the growth fraction is relatively small. Such toxicities can not be predicted based on the chemical structure of the drugs, are often not detected in preclinical studies, and are encountered frequently for the first time in clinical studies. Further, unlike most of the proliferative-dependent toxicities, the unpre dicted toxicities are usually irreversible or only partially reversible upon cessation of drug administration. Because of this, the unpredicted toxicities are referred to as dose limiting. They represent a significant barrier to the ultimate efficacy of several of our most important anticancer drugs."